PD-1 inhibitor combined with lenvatinib for unresectable liver cancer as the conversion therapy: An open-label, non-randomized, phase IV study.

Wenwen Zhang,Shichun Lu,Bingyang Hu,Tao Wan,Hongguang Wang,Jun Han,Ze Zhang,Junning Cao,Xianlei Xin,Yingwei Pan,Minggen Hu,Ming-Yi Chen,Yongliang Chen,Zhanyu Yang,Shou-Wang Cai,Wenbin Ji,Chenggang Li,Shuang Tong,Feilong Zhao,Xiaochen Zhao

PD-1 inhibitor combined with lenvatinib for unresectable liver cancer as the conversion therapy: An open-label, non-randomized, phase IV study.

2021

e16173Background: The combination of lenvatinib and PD-1 inhibitor has shown to be a promising regimen for advanced hepatocellular carcinoma (HCC). We aimed to assess the feasibility of conversion ...

Keywords:

Hepatocellular carcinoma
Internal medicine
Medicine
Regimen
Oncology
Liver cancer
Lenvatinib
open label
Programmed cell death 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations